Increasing quantitative estrogen receptor beta expression in meningioma after exogenous hormonal contraception exposure
Abstract
Factors influencing estrogen receptor (ER) and progesterone receptor (PR) expression in meningioma are unclear. This study aimed to assess the expression of ER and PR in females with meningioma in relation to patient exogenous hormonal exposure. Cross-sectional study of females with meningioma in Yogyakarta, Indonesia, between 2010 to 2016 was conducted. Histories were obtained through interviews. Expressions of ERa, ERb, and PR were assessed from paraffin blocks containing patients’ meningioma tissue using real-time quantitative polymerase chain reaction (RT-qPCR). The study identified 28 female meningioma patients with a mean age of 45.6 ± 6.8 yr. Increased ERb expression was found in the ³10-yr group of hormonal contraception exposure duration (<10 yr vs ³10 yr = 7.63 (2.3-11.31) vs 12.56 (1.87-42.22), p=0.038). Positive correlation was found between ERb expression and the duration of hormonal contraception exposure (r=0.432; p=0.022), especially progesterone-only contraception (r=0.5; p=0.048), while no significant correlation was found between ERb expression and duration of progesterone-estrogen contraception exposure (r=0.382; p=0.22). No significant analyses were found in ERa and PR. In conclusion, expression of ERβ in meningioma increased in accordance with exogenous hormonal exposure duration, especially progesterone. This finding suggests the importance of ERβ in meningioma and warrants further study as a potential biomarker.
References
Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010; 99(3):307-14.
https://doi.org/10.1007/s11060-010-0386-3
Barnholtz-Sloan JS, Kruchko C. Meningiomas causes and risk factors. Neurosurg Focus 2007; 23(4):e2.
https://doi.org/10.3171/FOC-07/10/E2
Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z. Reproductive and exogenous hormone factors in relation to risk of meningioma in women: A meta-analysis. PLoS One 2013; 8(12):e83261.
https://doi.org/10.1371/journal.pone.0083261
Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M, et al. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epid 2006; 164(7):629-36.
https://doi.org/10.1093/aje/kwj254
Shu X, Jiang Y, Wen T, Lu S, Yao L, Meng F. Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching. Asia Pac J Clin Oncol 2019; 15(5):e147-e53.
https://doi.org/10.1111/ajco.13138
Custer B, Longstreth WTJr, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: A population-based case-control study. BMC Cancer 2006; 6:152.
https://doi.org/10.1186/1471-2407-6-152
Koper JW, Foekens JA, Braakman R, Lamberts SWJ. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells. Cancer Res 1990; 50(9):2604-7.
Shimizu J, Matsumoto M, Yamazaki E, Yasue M. Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir 2008; 48(5):227-30.
https://doi.org/10.2176/nmc.48.227
Kalamarides M, Peyre M. Dramatic shrinkage with reduced vascularization of large meningiomas after cessation of progestin treatment. World Neurosurg 2017; 101:814 e7- e10.
https://doi.org/10.1016/j.wneu.2017.03.013
Deipolyi AR, Han SJ, Parsa AT. Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy. J Clin Neurosci 2010; 17(10):1324-6.
https://doi.org/10.1016/j.jocn.2010.01.036
Ing NH, Tornesi MB. Estradiol up-regulates estrogen receptor and progesterone receptor gene expression in specific ovine uterine cells. Biol Reprod 1997; 56(5):1205-15.
https://doi.org/10.1095/biolreprod56.5.1205
Brown TJ, MacLusky NJ. Progesterone modulation of estrogen receptors in microdissected regions of the rat hypothalamus. Mol Cell Neurosc 1994; 5(3):283-90.
https://doi.org/10.1006/mcne.1994.1033
Read LD, Snider CE, Miller JS, Greene GL, Katzeneilenbogen BS. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol 1988; 2(3):263-71.
https://doi.org/10.1210/mend-2-3-263
Agopiantz M, Carnot M, Denis C, Martin E, Gauchotte G. Hormone receptor expression in meningiomas: A systematic review. Cancers (Basel) 2023; 15(3):980.
https://doi.org/10.3390/cancers15030980
Leaes CGS, Meurer RT, Coutinho LB, Ferreira NP, Pereira-Lima JFS, da Costa Oliveira M. Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells. Neuropathology 2010; 30(1):44-9.
https://doi.org/10.1111/j.1440-1789.2009.01047.x
Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 1999; 42(2):109-16.
https://doi.org/10.1023/a:1006158514866
Speirs V, Boyle-Walsh E, Fraser WD. Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in-vitro cell cultures to steroid hormones. Int J Cancer 1997; 72(5):714-9.
https://doi.org/10.1002/(sici)1097-0215(19970904)72:5<714::aid-ijc2>3.0.co;2-v
Chen P, Li B, Ou-Yang L. Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne) 2022; 13:839005.
https://doi.org/10.3389/fendo.2022.839005
Supartoto A, Sasongko MB, Respatika D, Mahayana IT, Pawiroranu S, Kusnanto H, et al. Relationships between neurofibromatosis-2, progesterone receptor expression, the use of exogenous progesterone, and risk of orbitocranial meningioma in females. Front Oncol 2019; 8:651.
https://doi.org/10.3389/fonc.2018.00651
Supartoto A, Mahayana IT, Heriyanto DS, Sasongko MB, Respatika HD, Sakti DH, et al. Neurofibromatosis type 2 gene mutation and progesterone receptor messenger RNA expression in the pathogenesis of sporadic orbitocranial meningioma. Int J Ophthalmol 2019; 12(4):571-6.
https://doi.org/10.18240/ijo.2019.04.07
Rudra CL, Williams MA. BMI as a modifying factor in the relations between age at menarche, menstrual cycle characteristics, and risk of preeclampsia. Gynecol Endocrinol 2005; 21(4):200-5.
https://doi.org/10.1080/09513590500168431
Abetew DF, Enquobahrie DA, Dishi M, Rudra CB, Miller RS, Williams MA. Age at menarche, menstrual characteristics, and risk of preeclampsia. ISRN Obstet Gynecol 2011; 2011:472083.
https://doi.org/10.5402/2011/472083
Andersen L, Friis S, Hallas J, Ravn P, Schroder HD, Gaist D. Hormone replacement therapy increases the risk of cranial meningioma. Eur J Cancer 2013; 49(15):3303-10.
https://doi.org/10.1016/j.ejca.2013.05.026
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131(6):803-20.
https://doi.org/10.1007/s00401-016-1545-1
Spiegl-Kreinecker S, Lotsch D, Neumayer K, Kastler L, Gojo J, Pirker C, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol 2018; 20(12):1584-93.
https://doi.org/10.1093/neuonc/noy104
Ke HL, Ke RH, Li ST, Li B, Lu HT, Wang XQ. Expression of RACGAP1 in high grade meningiomas: A potential role in cancer progression. J Neurooncol 2013; 113(2):327-32.
https://doi.org/10.1007/s11060-013-1121-7
Smanik EJ, Calderon JJ, Muldoon TG, Mahesh VB. Effect of progesterone on the activity of occupied nuclear estrogen receptor in vitro. Mol Cell Endocrinol 1989; 64(1):111-7.
https://doi.org/10.1016/0303-7207(89)90071-3
Aguirre C, Jayaraman A, Pike C, Baudry M. Progesterone inhibits estrogen-mediated neuroprotection against excitotoxicity by down-regulating estrogen receptor-beta. J Neurochem 2010; 115(5):1277-87.
https://doi.org/10.1111/j.1471-4159.2010.07038.x
Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther 2011; 89(1):44-55.
https://doi.org/10.1038/clpt.2010.226
Zhou M, Sareddy GR, Li M, Liu J, Luo Y, Venkata PP, et al. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways. Sci Rep 2019; 9(1):6124.
https://doi.org/10.1038/s41598-019-42313-8
Warner M, Gustafsson JA. The role of estrogen receptor beta (ERbeta) in malignant diseases--a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 2010; 396(1):63-6.
https://doi.org/10.1016/j.bbrc.2010.02.144
Gallo D, Stefano ID, Prisco MG, Scambia G, Ferrandina G. Estrogen receptor beta in cancer an attractive target for therapy. Curr Pharm Des 2012; 18(19):2734-57.
https://doi.org/10.2174/138161212800626139
Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study C. Lifestyle factors and primary glioma and meningioma tumours in the million women study cohort. Br J Cancer 2008; 99(1):185-90.
https://doi.org/10.1038/sj.bjc.6604445
Schüz J, Böhler E, Berg G, Schlehofer B, Hettinger I, Schlaefer K, et al. Cellular phones, cordless phones, and the risks of glioma and meningioma (Interphone Study Group, Germany). Am J Epid 2006; 163(6):512-20.
https://doi.org/10.1093/aje/kwj068
Michaud DS, Gallo V, Schlehofer B, Tjonneland A, Olsen A, Overvad K, et al. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers Prev 2010; 19(10):2562-9.
https://doi.org/10.1158/1055-9965.EPI-10-0447
Cowppli-Bony A, Bouvier G, Rue M, Loiseau H, Vital A, Lebailly P, et al. Brain tumors and hormonal factors: Review of the epidemiological literature. Cancer Causes Control 2011; 22(5):697-714.
https://doi.org/ 10.1007/s10552-011-9742-7
Wu M-H, Lu C-W, Chang F-M, Tsai S-J. Estrogen receptor expression affected by hypoxia inducible factor-1a in stromal cells from patients with endometriosis. Taiwan J Obstet Gynecol 2012; 51(1):50-4.
https://doi.org/10.1016/j.tjog.2012.01.010
Cho J, Kim D, Lee S, Lee Y. Cobalt chloride-induced estrogen receptor alpha down-regulation involves hypoxia-inducible factor-1alpha in MCF-7 human breast cancer cells. Mol Endocrinol 2005; 19(5):1191-9.
https://doi.org/10.1210/me.2004-0162
Reszec J, Hermanowicz A, Rutkowski R, Bernaczyk P, Mariak Z, Chyczewski L. Evaluation of mast cells and hypoxia inducible factor-1 expression in meningiomas of various grades in correlation with peritumoral brain edema. J Neurooncol 2013; 115(1):119-25.
https://doi.org/10.1007/s11060-013-1208-1
Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia role of the HIF system. Nat Med 2003; 9(6):677-84.
https://doi.org/10.1038/nm0603-677
Ando H, Natsume A, Iwami K, Ohka F, Kuchimaru T, Kizaka-Kondoh S, et al. A hypoxia-inducible factor (HIF)-3alpha splicing variant, HIF-3alpha4 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3alpha4. Biochem Biophys Res Commun 2013; 433(1):139-44.
https://doi.org/10.1016/j.bbrc.2013.02.044
Harland TA, Freeman JL, Davern M, McCracken DJ, Celano EC, Lillehei K, et al. Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. J Neurooncol 2018; 136(2):327-33.
https://doi.org/10.1007/s11060-017-2656-9
Xue Q, Lin Z, Cheng YH, Huang CC, Marsh E, Yin P, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod 2007; 77(4):681-7.
https://doi.org/10.1095/biolreprod.107.061804
Bulun SE, Monsavais D, Pavone ME, Dyson M, Xue Q, Attar E, et al. Role of estrogen receptor-beta in endometriosis. Semin Reprod Med 2012; 30(1):39-45.
https://doi.org/10.1055/s-0031-1299596
Haldosen LA, Zhao C, Dahlman-Wright K. Estrogen receptor beta in breast cancer. Mol Cell Endocrinol 2014; 382(1):665-72.
https://doi.org/10.1016/j.mce.2013.08.005
Zhao C, Matthews J, Tujague M, Wan J, Strom A, Toresson G, et al. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 2007; 67(8):3955-62.
https://doi.org/10.1158/0008-5472.CAN-06-3505
Zhou X-L, Fan W, Yang G, Yu M-X. The clinical significance of PR, ER, NF-B, and TNF-alpha in breast cancer. Dis Markers 2014; 2014:494581.
https://doi.org/10.1155/2014/494581
Ritte R, Lukanova A, Tjonneland A, Olsen A, Overvad K, Mesrine S, et al. Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: A cohort study. Int J Cancer 2013; 132(11):2619-29.
https://doi.org/10.1002/ijc.27913
Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjöblom P, Norgren A, et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 1998; 83(11):4092-6.
https://doi.org/10.1210/jcem.83.11.5287
Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 2011; 20(9):1883-91.
https://doi.org/10.1158/1055-9965.EPI-11-0465
Lord SJ, Bernstein L, Johnson KA, Malone KE, McDonald JA, Marchbanks PA, et al. Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: A case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17(7):1723-30.
https://doi.org/10.1158/1055-9965.EPI-07-2824
Kubo M, Fukutomi T, Akashi-Tanaka S, Hasegawa T. Association of breast cancer with meningioma: report of a case and review of the literature. Jpn J Clin Oncol 2001; 31(10):510-3.
https://doi.org/10.1093/jjco/hye109
Mukhopadhyay M, Das C, Kumari M, Sen A, Mukhopadhyay B, Mukhopadhyay B. Spectrum of meningioma with special reference to prognostic utility of ER,PR and Ki67 expression. J Lab Physicians 2017; 9(4):308-13.
https://doi.org/10.4103/JLP.JLP_158_16
Hua L, Zhu H, Li J, Tang H, Kuang D, Wang Y, et al. Prognostic value of estrogen receptor in WHO Grade III meningioma: A long-term follow-up study from a single institution. J Neurosurg 2018; 128(6):1698-706.
